Related Experiment Video
Updated: Dec 27, 2025
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
Published on: August 2, 2022
Targeted camptothecin delivery via silicon nanoparticles reduces breast cancer metastasis
Marietta Landgraf1, Christoph A Lahr1, Ishdeep Kaur2
1Centre in Regenerative Medicine, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, QLD, Australia.
Abstract:
In advanced breast cancer (BCa) patients, not the primary tumor, but the development of distant metastases, which occur mainly in the organ bone, and their adverse health effects are responsible for high mortality. Targeted delivery of already known drugs which displayed potency, but rather unfavorable pharmacokinetic properties, might be a promising approach to overcome the current limitations of metastatic BCa therapy. Camptothecin (CPT) is a highly cytotoxic chemotherapeutic compound, yet poorly water-soluble and non-specific. Here, CPT was loaded into porous silicon nanoparticles (pSiNP) displaying the epidermal growth factor receptor (EGFR)-targeting antibody (Ab) cetuximab to generate a soluble and targeted nanoscale delivery vehicle for cancer treatment. After confirming the cytotoxic effect of targeted CPT-loaded pSiNP in vitro on MDA-MB-231BO cells, nanoparticles were studied in a humanized BCa bone metastasis mouse model. Humanized tissue-engineered bone constructs (hTEBCs) provided a humanized microenvironment for BCa bone metastases in female NOD-scid IL2Rgnull (NSG) mice. Actively targeted CPT-loaded pSiNP led to a reduction of orthotopic primary tumor growth, increased survival rate and significant decrease in hTEBC and murine lung, liver and bone metastases. This study demonstrates that targeted delivery via pSiNP is an effective approach to employ CPT and other potent anti-cancer compounds with poor pharmacokinetic profiles in cancer therapy.
Insights
Targeted nanoparticles deliver potent chemotherapy to reduce breast cancer metastasis. This approach enhances drug effectiveness and improves survival rates in advanced cancer patients.
Area of Science:
- Nanotechnology in oncology
- Drug delivery systems
- Breast cancer metastasis research
Background:
- Advanced breast cancer (BCa) mortality is primarily driven by bone metastases, not the primary tumor.
- Existing potent chemotherapeutics like Camptothecin (CPT) have poor water solubility and specificity, limiting their use.
- Targeted drug delivery offers a promising strategy to overcome limitations in metastatic BCa therapy.
Purpose of the Study:
- To develop a soluble and targeted nanoscale delivery vehicle for Camptothecin (CPT).
- To evaluate the efficacy of CPT-loaded porous silicon nanoparticles (pSiNP) targeting epidermal growth factor receptor (EGFR) in a humanized breast cancer bone metastasis model.
Main Methods:
- CPT was loaded into porous silicon nanoparticles (pSiNP) functionalized with cetuximab, an EGFR-targeting antibody.
- In vitro cytotoxicity was assessed on MDA-MB-231BO cells.
- In vivo studies utilized a humanized breast cancer bone metastasis mouse model with humanized tissue-engineered bone constructs (hTEBCs).
Main Results:
- Targeted CPT-loaded pSiNP demonstrated in vitro cytotoxicity.
- In vivo, targeted pSiNP reduced primary tumor growth, increased survival rates, and significantly decreased metastases in hTEBCs, lungs, liver, and bone.
- The nanoparticles effectively delivered CPT to metastatic sites.
Conclusions:
- Targeted delivery of CPT using pSiNP is an effective strategy for treating metastatic breast cancer.
- This approach enhances the therapeutic potential of potent anti-cancer drugs with poor pharmacokinetic properties.
- pSiNP-mediated targeted delivery shows promise for improving outcomes in advanced breast cancer patients.
